Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial

Fasching P, Quek RGW, Bhattacharyya H, Hurvitz SA, Rugo HS, Ettl J (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Berlin DE

DOI: 10.1093/annonc/mdz100.005

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Pfizer, Inc. US United States (USA) (US) UCLA Health US United States (USA) (US) Technische Universität München (TUM) DE Germany (DE) UCSF Helen Diller Family Comprehensive Cancer Center US United States (USA) (US)

How to cite

APA:

Fasching, P., Quek, R.G.W., Bhattacharyya, H., Hurvitz, S.A., Rugo, H.S., & Ettl, J. (2019). Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. In ANNALS OF ONCOLOGY. Berlin, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Fasching, Peter, et al. "Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial." Proceedings of the ESMO Breast Cancer, Berlin OXFORD: OXFORD UNIV PRESS, 2019.

BibTeX: Download